U.S. Markets close in 11 mins
  • S&P 500

    4,116.31
    -47.69 (-1.15%)
     
  • Dow 30

    33,928.32
    -228.37 (-0.67%)
     
  • Nasdaq

    11,911.20
    -202.58 (-1.67%)
     
  • Russell 2000

    1,944.01
    -28.60 (-1.45%)
     
  • Crude Oil

    78.46
    +1.32 (+1.71%)
     
  • Gold

    1,886.70
    +1.90 (+0.10%)
     
  • Silver

    22.32
    +0.14 (+0.64%)
     
  • EUR/USD

    1.0715
    -0.0016 (-0.1500%)
     
  • 10-Yr Bond

    3.6530
    -0.0210 (-0.57%)
     
  • Vix

    19.73
    +1.07 (+5.73%)
     
  • GBP/USD

    1.2066
    +0.0014 (+0.1182%)
     
  • USD/JPY

    131.4130
    +0.3410 (+0.2602%)
     
  • BTC-USD

    22,889.44
    -314.12 (-1.35%)
     
  • CMC Crypto 200

    527.13
    -9.77 (-1.82%)
     
  • FTSE 100

    7,885.17
    +20.46 (+0.26%)
     
  • Nikkei 225

    27,606.46
    -79.01 (-0.29%)
     

Germany's Bayer secures U.S. FDA approval for hemophilia A therapy

March 17 (Reuters) - The U.S. Food and Drug Administration approved Bayer AG's therapy for the most common form of hemophilia, about three weeks after the treatment got the green signal in Europe, the company said on Thursday.

The therapy, Kovaltry, is designed to prevent and control bleeding in patients with hemophilia A when used prophylactically two or three times per week, and was approved by the European Commission on Feb. 22.

Due to a fault in a gene that regulates the body's production of clotting factors, people with hemophilia are susceptible to spontaneous bleeding as well as severe bleeding following injury or surgery.

(Reporting by Natalie Grover in Bengaluru; Editing by Anupama Dwivedi)